Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS006 and Combination Therapy in NASH
NCT04147195Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of LYS006 in Nonalcoholic steatohepatitis (NASH), sponsored by Novartis. Started Jun 2020; status: terminated.
02
Drugs
LYS006
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04147195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147195.